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Abstract
Background: Brucella spp. are Gram-negative, facultative intracellular bacteria that cause brucellosis, one of the
commonest zoonotic diseases found worldwide in humans and a variety of animal species. While several animal
vaccines are available, there is no effective and safe vaccine for prevention of brucellosis in humans. VIOLIN (http://
www.violinet.org) is a web-based vaccine database and analysis system that curates, stores, and analyzes published
data of commercialized vaccines, and vaccines in clinical trials or in research. VIOLIN contains information for 454
vaccines or vaccine candidates for 73 pathogens. VIOLIN also contains many bioinformatics tools for vaccine data
analysis, data integration, and vaccine target prediction. To demonstrate the applicability of VIOLIN for vaccine
research, VIOLIN was used for bioinformatics analysis of existing Brucella vaccines and prediction of new Brucella
vaccine targets.
Results: VIOLIN contains many literature mining programs (e.g., Vaxmesh) that provide in-depth analysis of Brucella
vaccine literature. As a result of manual literature curation, VIOLIN contains information for 38 Brucella vaccines or
vaccine candidates, 14 protective Brucella antigens, and 68 host response studies to Brucella vaccines from 97 peer-
reviewed articles. These Brucella vaccines are classified in the Vaccine Ontology (VO) system and used for different
ontological applications. The web-based VIOLIN vaccine target prediction program Vaxign was used to predict new
Brucella vaccine targets. Vaxign identified 14 outer membrane proteins that are conserved in six virulent strains
from B. abortus, B. melitensis, and B. suis that are pathogenic in humans. Of the 14 membrane proteins, two
proteins (Omp2b and Omp31-1) are not present in B. ovis,aBrucella species that is not pathogenic in humans.
Brucella vaccine data stored in VIOLIN were compared and analyzed using the VIOLIN query system.
Conclusions: Bioinformatics curation and ontological representation of Brucella vaccines promotes classification
and analysis of existing Brucella vaccines and vaccine candidates. Computational prediction of Brucella vaccine
targets provides more candidates for rational vaccine development. The use of VIOLIN provides a general approach
that can be applied for analyses of vaccines against other pathogens and infection diseases.
Background
Brucella is a Gram-negative, facultative intracellular
bacterium that causes brucellosis in humans and ani-
mals [1]. Brucella are taxonomically placed in the
alpha-2 subdivision of the class Proteobacteria. Tradi-
tionally there are six species of Brucella based on the
preferential host specificity: B. melitensis (goats), B.
abortus (cattle), B. suis (swine), B. canis (dogs), B. ovis
(sheep) and B. neotomae (desert mice). The first four
species listed in decreasing order of severity are patho-
genic to humans making brucellosis a zoonotic disease.
These bacteria are also amenable for use in biological
warfare and bio-terrorism. Recently, two new species
B. cetaceae (cetacean) and B. pinnipediae (seal) have
been described [2]. Complete genome sequences of 10
Brucella strains are currently available in the NCBI
* Correspondence: yongqunh@umich.edu
Unit for Laboratory Animal Medicine, Department of Microbiology and
Immunology, and Center for Computational Medicine and Bioinformatics,
University of Michigan Medical School, Ann Arbor, MI 48109, USA
He and Xiang Immunome Research 2010, 6(Suppl 1):S5
http://www.immunome-research.com/content/6/S1/S5
IMMUNOME RESEARCH
© 2010 He and Xiang; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.RefSeq database. Four genomes from B. abortus, B.
melitensis,a n dB. suis have been extensively analyzed
[3-6]. While animal brucellosis vaccines are commer-
cially available, there is no effective and safe human
vaccine against virulent Brucella infections. Extensive
studies on Brucella have recently been concentrated
on understanding the mechanisms for protective Bru-
cella immunity and the development of effective
human brucellosis vaccines.
VIOLIN (http://www.violinet.org) is a web-based vac-
cine database and analysis system. VIOLIN contains
general information on microbial pathogenesis, host
ranges, and host protective immunity, as well as vac-
cine-specific information such as vaccine type, prepara-
tion method, genetically engineered genes, and host
responses in various animal models. VIOLIN contains
information about 454 vaccines and vaccine candidates
for 73 pathogens. VIOLIN contains many bioinformatics
tools for vaccine literature mining, vaccine data analysis
and integration, and vaccine target prediction. For
example, VIOLIN includes Vaxmesh and Vaxpresso pro-
grams that may be used to mine vaccine literature based
on MeSH controlled vocabulary and natural language
processing (NLP), respectively. Dr. Yongqun He, the
founder of the VIOLIN initiated and leads community-
based development of the Vaccine Ontology to support
vaccine integration and automated reasoning. A web-
based vaccine target prediction program Vaxign avail-
able in VIOLIN is used to predict vaccine targets based
on genome sequence analysis using a reverse vaccinol-
ogy strategy.
As of May 13, 2010, more than 2,000 Brucella vac-
cine-related literature papers were searchable in
PubMed, and 10 Brucella genomes have been published
in the NCBI RefSeq database. To support Brucella vac-
cine research and development, we systematically
curated from the literature existing Brucella vaccine
information, which are stored in VIOLIN for query and
further analyses. Different VIOLIN tools are also used
to analyze Brucella vaccines and predict new vaccine
targets.
Results
Brucella vaccine literature mining in VIOLIN
All Brucella vaccine-related articles were downloaded
from PubMed and stored in VIOLIN. Information for
these articles was processed and used for varying litera-
ture mining applications in VIOLIN. For example, Vax-
mesh, a MeSH-based vaccine literature visualization and
mining tool in VIOLIN, was used (Figure 1). The Medi-
cal Subject Headings (MeSH; http://www.nlm.nih.gov/
mesh/) is the controlled vocabulary thesaurus developed
by the National Library of Medicine (NLM) to index
articles deposited for the MEDLINE/PubMed database.
There are over 25,000 MeSH terms organized in a hier-
archical fashion based on 15 top-level categories. The
MeSH hierarchical structure permits literature searching
at various levels of specificity. Vaxmesh provides an
interactive web interface for users to locate articles
using MeSH terms in a hierarchical MeSH tree struc-
ture. Figure 1 demonstrates a MeSH hierarchy for the
term “Gene Deletion”. This major MeSH term is asso-
ciated with five papers in Brucella v a c c i n ea r e a( F i g u r e
1A-1B). A click on the MeSH term links the program to
another VIOLIN web page that reveals detailed informa-
tion about each of the five papers. A web link to
PubMed is also available (Figure 1C). According the
MeSH indexing, those articles associated with Brucella
vaccines also cover different areas such as anatomy (261
articles), physical sciences (194 articles), and geographic
locations (47 articles) (Figure 1).
Vaxperts is a new MeSH-based VIOLIN program that
provides a literature-based social network of vaccine
experts based on their publication records in PubMed.
Vaxperts allows vaccine experts to find their co-authors
and co-authors’s co-authors of shared publications. This
approach facilitates collaborative vaccine research and
development. For example, a search for the keyword
“Brucella” in Vaxperts resulted in the listing of 2454
authors that have contributed to at least one Brucella
vaccine article.
VIOLIN also contains three additional literature
mining programs. These are: Vaxpresso, a natural lan-
guage processing (NLP)-based vaccine literature mining
program; VIOLIN Litesearch, an advanced keyword-
and category-based search for vaccine literature; and
Vaxlert, a literature alert program that provides periodi-
cal literature updates through Emails based on the spe-
cification of a VIOLIN user.
Brucella vaccines curated in VIOLIN
With many literature mining programs available in VIO-
LIN, it is possible to make manual curation of Brucella
vaccine information more efficient. Brucella vaccine
curation was performed using a web-based literature
mining and curation system called Limix [7,8]. Limix
was developed to efficiently combine semi-automatic lit-
erature mining, manual curation, and data submission. .
All curated data includes references. The curated data is
published in VIOLIN and avai l a b l ef o rq u e r yo n l ya f t e r
it is critically reviewed and verified by an expert.
VIOLIN contains 38 curated Brucella vaccines or vac-
cine candidates that have been officially licensed or pro-
ven to provide protection in an animal model (Table 1).
Specifically, VIOLIN includes 20 B. abortus vaccines, 16
B. melitensis vaccines, and two B. suis vaccines. Among
them, four Brucella vaccines are licensed for commercial
uses in cattle, sheep, goat, and pigs. All others are
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induce protection in vivo against virulent Brucella chal-
lenges at least in some laboratory models (mostly in the
mouse model). In terms of vaccine types, 1, 8, 10, and
19 vaccines are bacterial vector vaccine, DNA vaccines,
subunit vaccines, and live attenuated vaccines,
respectively.
Ontology representation of Brucella vaccines
A biomedical ontology represents the consensus-based
controlled vocabularies of terms and relations which are
logically formulated in such a way as to promote auto-
mated reasoning. Ontologies are able to structure com-
plex biomedical domains and relate the myriad of data
to shared understanding of biomedicine. Ontologies can
be used for different purposes. The Gene Ontology
(GO) is a well-known example of an ontology created
for the primary purpose of providing controlled and
standardized terms for naming different types of biologi-
cal processes, cellular components, and molecular func-
tions [9]. This ontology allows the common
representation of attributes of gene products regardless
of species of origin. Creating such ontology-based anno-
tations is highly valuable both for querying databases
and analyzing high throughput data. This has a signifi-
cant impact since as of August 2010, over 2,500 peer-
reviewed publications are identified through a PubMed
search of “Gene Ontology”, and approximately 35,000
hits are identified through a Google Scholar search
using the same keywords. Ontologies can also be used
for representation of encyclopedic knowledge, data
exchange, and computational data analysis and
reasoning.
The Vaccine Ontology (VO; http://www.violinet.org/
vaccineontology) is a collaborative, community-based
ontology in the vaccine domain. VO can be used for
vaccine data standardization, integration, and computer-
assisted reasoning. VO utilizes the Basic Formal
Ontology (BFO) (http://www.ifomis.org/bfo), a domain-
independent ontology, as an upper level ontology. The
VO was developed using the W3C standard Web Ontol-
ogy Language (OWL) (http://www.w3.org/TR/owl-guide/
). The latest version of VO is always available at http://
purl.obolibrary.org/obo/vo.owl. In addition, VO has
been listed in the OBO (Open Biomedical Ontologies)
website (http://www.obofoundry.org/cgi-bin/detail.cgi?
id=vaccine), and deposited in the NCBO BioPortal
(http://bioportal.bioontology.org/virtual/1172). To
Figure 1 Vaxmesh analysis of Brucella vaccine papers associated with the MeSH term “Gene Deletion”. (A) Visualization of MeSH
hierarchy in Vaxmesh after keyword “Brucella” search; (B) The two clickable numbers next to each MeSH term links to all publications with the
term as a MeSH term or a major MeSH term, respectively. A click on “5” next to the MeSH term “Gene Deletion” links to another page with
detailed citation information; (C) The PubMed record is accessible after a click on an article title in (B).
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and usages of VO terms and their relations, a VO Brow-
ser (http://www.violinet.org/vaccineontology/vobrowser/)
was developed.
As with other vaccines, Brucella vaccines in VO are
asserted using single inheritance based on Brucella spe-
cies. Figure 2A demonstrates the asserted hierarchy of
B. abortus vaccines in VO. As an OWL document, VO
also supports computational inference with an OWL
reasoner, such as FACT++ [10]. For example, RB51 is
asserted under Brucella abortus vaccine (Figure 2A).
S i n c eR B 5 1h a st h eq u a l i t i e so f‘live’ and ‘attenuated’,i t
is also inferred as a ‘live attenuated Brucella vaccine’
using FACT++ (Figure 2B). Figure 2 provides a
Table 1 Brucella vaccines curated in VIOLIN and listed in VO
# Vaccine names VO ID Type Licensed
Brucella abortus vaccines
1 B. abortus DNA vaccine pcDNA-SOD VO_0000018 DNA Research
2 B. abortus RB51 VO_0000021 LA Licensed
3 B. abortus strain 19 VO_0000022 LA Licensed
4 B. abortus DNA vaccine encoding BCSP31, SOD and L7/L12 VO_0000321 DNA Research
5 B. abortus subunit vaccine using L7/L12 VO_0000323 Sub Research
6 Brucellaabortus bacA mutant VO_0000347 LA Research
7 B. recombinant SurA protein vaccine VO_0000358 Sub Research
8 B. recombinant DnaK protein vaccine VO_0000373 Sub Research
9 B. abortus DNA vaccine using L7/L12 and Omp16 VO_0000374 DNA Research
10 B. abortus DNA vaccine encoding L7/L12 and P39 VO_0000385 DNA Research
11 B. abortus with znuA deletion VO_0000386 LA Research
12 B. abortus porin-S-LPS VO_0000403 Sub Research
13 B. abortus RB51WboA VO_0000404 LA Research
14 Recombinant O. anthropi 49237SOD VO_0000407 BT Research
15 B. abortus pcDNA-BLS VO_0000421 DNA Research
16 Escheriosome delivery of B. abortus L7/L12 VO_0000423 Sub Research
17 NPAP Brucella vaccine VO_0000450 IA Research
18 B. abortus strain RB51SOD VO_0000720 LA Research
19 B. abortus strain 45/20 VO_0000723 LA Research
20 B. abortus S19 with P39 deletion VO_0000826 LA Research
Brucella melitensis vaccines
21 B. melitensis Rev. 1 with bp26 and omp31 deletions VO_0001171 LA Research
22 B. melitensis strain VTRM1 VO_0000300 LA Research
23 B. melitensis lipopolysaccharide vaccine VO_0000311 Sub Research
24 B. melitensis LPS-GBOMP noncovalent complex VO_0000312 Sub Research
25 B. melitensis DNA vaccine encoding Omp31 VO_0000325 DNA Research
26 B. melitensis bp26 deletion vaccine VO_0000338 LA Research
27 B. melitensis WR201 VO_0000345 LA Research
28 B. ovis microparticle subunit vaccine VO_0000354 Sub Research
29 microencapsulated B. melitensis mutant vaccine VO_0000398 LA Research
30 B. melitensis Bp26 and Tf vaccine VO_0000411 Sub Research
31 B. melitensis P39 recombinant protein vaccine VO_0000412 LA Research
32 recombinant chimera BLSOmp31 VO_0000413 Sub Research
33 B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 VO_0000436 DNA Research
34 B. melitensis Rev. 1 with P39 deletion VO_0000633 LA Research
35 B. melitensis strain Rev. 1 VO_0000710 LA Licensed
36 Brucella DNA vaccine encoding chimera BLSOmp31 VO_0001144 DNA Research
Brucella suis vaccines
37 B. suis strain VTRS1 VO_0000303 LA Research
38 B. suis strain 2 VO_0000722 LA Licensed
Note: The abbreviations LA, Sub, DNA, Con, IV, and BV represent live attenuated vaccine, subunit vaccine, DNA vaccine, conjugation vaccine, inactivated vaccine,
and bacterial vector vaccine, respectively.
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computational reasoning.
VO has been used in many applications associated
with Brucella vaccines. It can be used to improve
PubMed searching efficiencyi nt h ev a c c i n ed o m a i n .A
user case study would be to search “live attenuated Bru-
cella vaccine” in PubMed. As of April 10, 2009, a direct
PubMed search of this string of keywords returned 56
papers (or PubMed hits). VO includes 13 live attenuated
Brucella vaccines that have the qualities of ‘live’ and
‘attenuated’.W h e nt h e s es p e c i f i cBrucella vaccine terms
were also included in a PubMed search, the number of
positive paper hits in PubMed increased by more than
10-fold [11]. The combination of VO with SciMiner, a
literature mining program, significantly improves
PubMed searching efficiency in the general vaccine
domain [12]. It was also found that the application of
VO dramatically increased the performance of vaccine-
induced IFN- interaction networks [13].
Besides vaccine hierarchy, VO can also be used to
represent (or model) vaccine investigation. As demon-
strated in our two recent reports, vaccine protection
investigation can be represented in VO by three contin-
uous steps: vaccination, pathogen challenge, and vaccine
efficacy measurement [14,15]. A measurement of vac-
cine efficacy can be assessed by host survival for the
pathogens (e.g., Influenza virus) which kill the infected
host (e.g., mouse) [14] or by pathogen colony forming
units (CFU), a measurement for those pathogens (e.g.,
Brucella) which cannot kill infected host but exhibit
diminished replication in a vaccinated host than that in
unvaccinated host [15]. It is hypothesized that some
parameters will play more important roles than others
in determining the protection efficacy of Brucella vac-
cines. To test this hypothesis, the data for 151 groups of
Brucella vaccine protection investigations were collected
in VIOLIN from peer-reviewed literature publications
and analyzed using ANOVA. Out of 16 parameters, 10
were found statistically significant (P-value <0.05) in
contributing to protection based on a statistical
ANOVA analysis. Examples of these parameters
included vaccine strain, vaccine viability, vaccination
route, vaccination dose. However, other six parameters,
including IL-12 vaccine adjuvant, mouse sex, vaccination
route, animal age, vaccination-challenge interval, and
challenge dose, were not found statistically significant
(P-value > 0.05). A careful study of this use case led to
building and validating an ontology-based semantic fra-
mework to formally represent ANOVA [15]. Such an
ontology-based representation of biomedical data for
statistical analysis allows data consistency checking and
data sharing in the Semantic Web [16].
Literature curation of Brucella protective antigens
The VIOLIN Protegen program stores protective anti-
gens that have been verified experimentally to induce
protective immunity. Protegen contains 14 protective
Brucella antigens (Table 2). Among the 14 Brucella
Figure 2 VO hierarchy of Brucella vaccines. (A) Asserted hierarchy; (B) Inferred hierarchy.
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The other nine proteins are located in cytoplasm (5 pro-
teins), periplasm (4 proteins), and cytoplasmic
membrane (1 protein).
For vaccine development against Brucella infections
where T cell response is critical, subcellular localization
is not usually an issue since a T cell response could be
directed to any protein target. Our curated results con-
firm that protective Brucella antigens may occur in dif-
ferent subcellular locations.
Prediction of potential Brucella vaccine targets
Reverse vaccinology is an emerging vaccine development
approach that starts with the prediction of vaccine targets
using bioinformatics screening of an entire genome of a
pathogenic organism [17]. As part of VIOLIN, Vaxign is
the first web-based vaccine design program that predicts
vaccine targets based on reverse vaccinology [18,19]. The
Vaxign computational pipeline includes the following
features: subcellular localization, topology (transmem-
brane helices and beta barrel structure), adhesin prob-
ability, similarity to other pathogen sequences, similarity
to host genome sequences (e.g., human or mouse), and
MHC class I and II epitope predictions. To predict Bru-
cella vaccine targets, all 10 sequenced Brucella genomes
available in NCBI RefSeq were used for a Vaxign analysis.
As with other intracellular pathogens, protection
against Brucella infections requires cell-mediated immu-
nity (CMI). Secreted pathogen proteins are likely to sti-
mulate cytotoxic T lymphocyte (CTL) responses [20].
However, no Brucella protein has been found to be
secreted in any in vitro culture in a standard culture
medium. An O-sialoglycoprotein endopeptidase (Gcp;
RefSeq: YP_415230.1) in B. abortus strain 2308 was
identified by Vaxign to be a potential secreted protein.
This protein is also conserved in the other virulent
B. abortus, B. melitensis, and B. suis strains.
Vaxign was used to predict Brucella outer membrane
proteins (OMP) as potential vaccine targets using
B. abortus strain 2308 genome [6] as the seed genome
(Figure 3). Among 3034 proteins in this genome, 32
were identified as OMPs. These OMPs from B. abortus
strain 2308 are listed in Table 3. Some specific groups
such as cell wall/membrane/envelope biogenesis and cell
motility were enriched based on the COG analysis [21].
Two proteins among the 32 OMPs contain more than
one transmembrane spanning region each. These two
proteins are excluded for further consideration since the
presence of multiple transmembrane spanning regions
may make the purification of such recombinant proteins
difficult [22]. Adhesins present in microbial pathogens
are essential for bacterial invasion and survival and
represent possible targets for vaccine development. If
only adhesins are considered, 10 out of the remaining
30 proteins have a probability < 0.51 for being an adhe-
sin and hence were discarded. Fifteen out the remaining
20 proteins are conserved in the genomes from virulent
B. abortus strain 9-941, B. melitensis strain 16M and
ATCC 23457, and B. suis strains 1330 and ATCC
23445. Each of these strains is pathogenic to humans.
One protein (BAB1_1944) has homology with human
and mouse proteomes. Among these 14 predicted Bru-
cella vaccine targets, Omp25 (YP_414164.1) and
Omp31-1 (YP_414995.1) have been verified to be pro-
tective Brucella antigens [23,24]. The list of predicted
targets also includes two flagellar hook proteins FlgE
(YP_419225.1) and FlgK (YP_419224.1), one porin pro-
tein Omp2b (YP_414102.1), and two TonB-dependent
receptor proteins BAB1_1367 and BAB2_1150. The
r o l e so ft h e s ep o t e n t i a lp r o t e i n sa sp r o t e c t i v eBrucella
Table 2 Brucella protective antigens verified experimentally
# Symbol Locus tag Protein Description Location References (PMIDs)
1 BLS CAA86936 Brucella lumazine synthase Cytoplasm 11953389
2 L7/L12 BRURPL712X Ribosomal protein L7/L12 Cytoplasm 8873388
3 P39 ABM67295 sugar-binding 39-kDa protein Periplasm 11447155
4 Bfr BAB2_0675 Ferritin:Bacterioferritin Cytoplasm 11447155
5 Bp26 BMEI0536 Periplasmic immunogenic protein Periplasm 17239499
6 DnaK BruAb1_2100 Molecular chaperone DnaK Cytoplasm 17686554
7 IalB BMEI1584 Invasion protein B Cytoplasmic membrane 17049676
8 Omp16 BAB1_1707 Outer membrane protein MotY Outer membrane 18981242
9 Omp19 BAB1_1930 Lipoprotein Omp19 Outer membrane 18981242
10 Omp25 BMEI1249 25 kDa outer-membrane immunogenic protein precursor Outer membrane 18981242
11 Omp31 BAB1_1639 OmpA-like transmembrane domain Outer membrane 17014873
12 SodC BAB2_0535 Cu/Zn superoxide dismutase Periplasm 15039330
13 SurA BAB1_0706 Peptidyl-prolyl cis-trans isomerase Periplasm 17686554
14 Tig BMEI1069 Trigger factor Cytoplasm 17239499
Abbreviations: TMH, transmembrane helixes; Adhesin Prob., Adhesin probability; Con-ed represents the conserved proteins among five other genomes from virulent
B. abortus strain 9-941, B. melitensis strains 16M and ATCC 23457, and B. suis strains 1330 and ATCC 23445; Host Simil., similarity to human and mouse genomes.
He and Xiang Immunome Research 2010, 6(Suppl 1):S5
http://www.immunome-research.com/content/6/S1/S5
Page 6 of 12antigens have not been studied. The flagellar protein
FlgJ appears in B. abortus strains 2308 and 9-941, B.
melitensis strain 16M, and B. suis strain ATCC 23445;
however, FlgJ is absent from B. suis strain 1330 and B.
microti strain CCM 4915. Brucella flagellar genes have
recently been found important in Brucella survival in
vivo [25]. It remains unknown whether these Brucella
flagellar genes can be used for Brucella vaccine
development.
To develop a human Brucella vaccine, those Brucella
proteins that exist in Brucella strains pathogenic to
humans but are absent in Brucella strains that are non-
pathogenic to humans would be ideal for vaccine devel-
opment. Our studies have identified two proteins,
Omp2b (YP_414102.1) and Omp31-1 (YP_414995.1),
which are conserved in the above mentioned virulent B.
abortus, B. melitensis,a n dB. suis strains that are patho-
genic to humans, but absent from B. ovis that is non-
pathogenic to humans. Omp2b and Omp31 are two
major outer membrane proteins in B. abortus [26]. It is
likely that these two proteins are critical for human-spe-
cific Brucella infections. If a human Brucella vaccine is
developed, these two proteins are considered as priority
antigens. A further bioinformatics analysis indicates that
the porin protein Omp2b does not exist in live attenu-
ated B. abortus vaccine strain 19, suggesting that
Omp2b likely contributes to the attenuation of this
mutant. Omp2b also exists in B. canis that is weakly
pathogenic to humans. However, Omp31-1 does not
exist in B. canis.
Vaxign identified 46 Brucella periplasmic proteins that
are conserved in all B. abortus, B. melitensis, and B. suis
genomes and lack sequence similarity with proteins in
human or mouse genomes. The values of these proteins
for vaccine development also deserve further analysis.
Using the same criteria (sequence conservation and dis-
similarity from human or mouse proteins), Vaxign
detected approximately 1,000 cytoplasmic proteins. It is
impractical to individually test this high number of pro-
teins for vaccine development. Considering only five
cytoplasmic proteins have been experimentally con-
firmed to be protective antigens out of 1,000 conserved
cytoplasmic proteins (Table 2), it is much less likely that
cytoplasmic proteins serve as protective antigens com-
pared to outer membrane and periplasmic proteins.
Vaxign also contains an epitope prediction component
that can predict MHC class I and II binding epitopes
[19]. The addition of epitope prediction allows further
analysis for the existence of potential Brucella vaccine
targets.
Other programs in VIOLIN
VIOLIN provides user-friendly web interface for users to
query Brucella vaccine data in VIOLIN. For example,
Vaxquery is a user-friendly web query tool to query vac-
cine data (Figure 4).
VIOLIN VBLAST is a customized BLAST sequence
similarity search program. The BLAST library in
VBLAST includes those vaccine-associated genes,
including protective antigens, virulent factors whose
mutations lead to live attenuated vaccine development,
and host protective immune factors. These vaccine-asso-
ciated genes can also be queried through our Vaxgen
web interface.
Two VIOLIN programs Vaxjo and Vaxvec permit ana-
lysis of vaccine adjuvants and vaccine vectors. The adju-
vants used for Brucella vaccine development include
Complete and Incomplete Freund’sA d j u v a n t s ,C p G ,
Cholera toxin (CT) adjuvant, Maltose binding protein
(MBP).
Figure 3 Prediction of Brucella vaccine targets using Vaxign. *,
represents five genomes from virulent B. abortus strain 9-941, B.
melitensis strains 16M and ATCC 23457, and B. suis strains 1330 and
ATCC 23445. **, represents the genome from B. ovis strain ATCC
25840; The indicated two proteins are Omp2b (YP_414102.1) and
Omp31-1 (YP_414995.1).
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# Locus Tag RefSeq # Symbol TMH Adhesin
Prob.
Con-
ed
Host
Simil.
Protein Notes
Cell Motility
1 BAB2_1097 YP_419224.1 FlgK 0 0.535 X flagellar hook-associated protein FlgK
2 BAB2_1098 YP_419225.1 FlgE 0 0.749 X flagellar hook protein FlgE
3 BAB1_0260 YP_413736.2 FlgJ 0 0.656 Flagellar protein FlgJ:Mannosyl-glycoprotein endo-beta-N-
acetylglucosamidase
4 BAB1_1726 YP_415076.1 1 0.229 X hypothetical protein
TonB-dependent Receptor Protein: Inorganic Ion Transport and Metabolism
5 BAB2_0233 YP_418452.1 0 0.405 X TonB-dependent receptor protein
6 BAB2_1150 YP_419272.1 0 0.691 X TonB-dependent receptor protein:Pollen allergen Poa pIX/Phl pVI,
C-terminal
7 BAB1_1367 YP_414742.1 0 0.655 X TonB-dependent receptor protein
ATP/GTP-binding Site Motif A (P-loop): Porin, Alpha proteobacteria type
8 BAB1_0659 YP_414101.1 Omp2a 0 0.611 Porin, alpha proteobacteria type
9 BAB1_0660 YP_414102.1 Omp2b 0 0.585 X Porin, alpha proteobacteria type
Cell wall/membrane/envelope Biogenesis
10 BAB1_0045 YP_413545.1 0 0.388 X Bacterial surface antigen (D15)
11 BAB1_0115 YP_413611.1 0 0.793 X outer membrane protein, putative
12 BAB1_0116 YP_413612.1 0 0.58 X outer membrane protein, putative
13 BAB1_0707 YP_414149.1 0 0.635 X Organic solvent tolerance protein
14 BAB1_0722 YP_414164.1 Omp25 0 0.554 X OmpA-like transmembrane domain
15 BAB1_1176 YP_414567.1 1 0.408 X Bacterial surface antigen (D15)
16 BAB1_1226 YP_414612.1 3 0.571 X MotY protein: OmpA/MotB domain
17 BAB1_1302 YP_414685.1 RopB 1 0.815 X hypothetical protein
18 BAB1_1579 YP_414943.1 1 0.669 X OmpW family
19 BAB1_1639 YP_414995.1 Omp31-
1
0 0.736 X OmpA-like transmembrane domain
20 BAB1_1707 YP_415057.1 0 0.371 X MotY protein: OmpA/MotB domain
21 BAB2_0314 YP_418525.1 1 0.649 X heat resistant agglutinin 1 precursor
22 BAB1_0963 YP_414386.1 0 0.415 X Outer membrane efflux protein
Replication, Recombination and Repair
23 BAB2_0636 YP_418811.1 0 0.299 X DNA topoisomerase I
24 BAB1_0121 YP_413617.1 0 0.162 X X DEAD/DEAH box helicase
Lipid Transport and Metabolism
25 BAB1_0967 YP_414390.1 0 0.764 Membrane protein involved in aromatic hydrocarbon degradation
Posttranslational Modification, Protein Turnover, Chaperones
26 BAB1_1944 YP_415281.1 1 0.518 X PpiC-type peptidyl-prolyl cis-trans isomerase
Unknown Function
27 BAB1_1705 YP_415055.1 0 0.594 X TPR repeat:Molluscan rhodopsin C-terminal tail
28 BAB1_1854 YP_415198.1 0 0.759 hypothetical protein
29 BAB2_0071 YP_418316.1 0 0.492 X hypothetical protein
30 BAB1_0069 YP_413569.1 0 0.886 hypothetical protein BAB1_0069
31 BAB1_0897 YP_414322.1 2 0.279 X Antifreeze protein, type I
32 BAB1_0942 YP_414367.1 1 0.346 X RNA-binding region RNP-1 (RNA recognition motif)
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Page 8 of 12Additionally, VIOLIN contains the information for
host responses to Brucella vaccines. Animal response
information can be searched through VIOLIN Vaxar
(http://www.violinet.org/vaxar). Currently, annotated
information for 68 host response studies of Brucella
vaccines is available in Vaxar. VIOLIN contains many
pages that are associated with other vaccine related
topics, such as vaccine conferences, manufacturers, and
useful web links.
Discussion
A large number of vaccine-related databases exist on the
web. There are many government-supported vaccine
databases. For example, the Centers for Disease Control
and Prevention (CDC) maintain a Vaccine Information
Statements (VISs) system (http://www.cdc.gov/vaccines/
pubs/vis/default.htm). The Center for Biologics Evalua-
tion and Research (CBER) under the Food and Drug
Administration (FDA) regulates vaccine products and
posts relevant information in their vaccine site: http://
www.fda.gov/cber/vaccines.htm. There is also a Vaccine
Adverse Event Reporting System (VAERS, http://vaers.
hhs.gov/), co-sponsored by FDA and CDC in USA.
Many agent-specific databases are also available, for
example, the HIV vaccine resource (http://www3.niaid.
nih.gov/research/topics/HIV/vaccines/default.htm) cre-
ated by the National Institute of Allergy and Infectious
Diseases (NIAID) at the National Institutes of Health
(NIH). Other vaccine resources include, the Vaccine
Page: http://www.vaccines.org/), the Vaccine Resource
Library (PATH, http://www.path.org/vaccineresources/),
and the Immunization Action Coalition (http://www.
immunize.org/). These databases primarily focus on
available information concerning existing licensed vac-
cines and vaccine regulation. VIOLIN is unique in that
it stores and analyzes research data concerning commer-
cial vaccines and vaccines under clinical trial or in early
stages of development [8].
Figure 4 Brucella vaccine analyses using VIOLIN Vaxquery. After typing the “live attenuated Brucella abortus vaccines” in the Vaxquery query
bar (A), 11 Brucella vaccines were displayed (B). Two vaccines (RB51 and RB51SOD) were chosen for advanced comparison (B). After query
settings were chosen (C), the results were displayed (E). All curated information has associated references which can be linked to PubMed (E).
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community effort and involves many experts in the vac-
cine and biomedical ontology communities [27]. With
the large number of vaccine data types and publications
available, VO is developed as an efficient strategy for
vaccine data standardization, retrieval, and integration.
VO makes it possible for computer programs to under-
stand various vaccine types and research data associated
with different vaccines. VO will also help to ensure that
data is annotated in a way that ensures comparability.
Therefore, VO-based software programs can be devel-
oped to support high throughput vaccine data proces-
sing and analysis. We are currently developing a VO-
based literature mining and curation program that
would increase the efficacy of vaccine literature mining
and manual curation. The VO-based literature mining
program will also relieve the burden of continuous data-
base updating. VO will also be used to integrate all vac-
cine data in VIOLIN, making vaccine information
exchange more efficient.
Compared to the traditional vaccine development
approach that starts from a wet laboratory, reverse vac-
cinology begins with dry laboratory bioinformatics ana-
lysis, which makes the vaccine development more
specific and efficient. Reverse vaccinology was first used
by Rino Rappuoli in the development of a vaccine
against serogroup B Neisseria meningitidis (MenB), the
major cause of sepsis and meningitis in children and
young adults [28]. Since then, this strategy has been
applied to many other pathogens such as Bacillus
anthracis [29], Streptococcus pneumoniae [30], and
Mycobacterium tuberculosis [31]. While the criteria for
vaccine prediction are known and many individual pro-
grams are available, it is still time consuming and
requires expertise in these individual programs to pre-
dict vaccine targets using genome sequences. Vaxign is
the first web-based automated pipeline that identifies
potential vaccine targets based on the reserve vaccinol-
ogy strategy [19]. Vaxign has been applied successfully
to predict vaccine targets for uropathogenic E. coli [19].
This study demonstrated that Vaxign can predict novel
Brucella vaccine targets. Experimental verification of
many of these targets is currently under way. Vaxign
also contains a program to predict immune epitopes
that bind to MHC class I and II molecules in different
animal species. Studies analyzing and ranking potential
immune epitopes from predicted Brucella proteins are
in progress. Promising epitopes will be tested in a wet
laboratory.
VIOLIN is also associated with other existing data
resources. For example, many VIOLIN programs (e.g.,
Vaxign and Protegen) obtain Brucella genome
sequences and share Brucella gene annotations with the
web-based Pathogen-host Interaction Data Integration
and Analysis System (PHIDIAS, http://www.phidias.us)
[32]. PHIDIAS focuses on the analysis of pathogen-host
interactions. Additionally, PHIDIAS contains the Bru-
cella Bioinformatics Portal, a web-based portal with a
special emphasis on Brucella genome annotation and lit-
erature mining [7]. PHIDIAS and BBP, also developed in
our group, integrate more than 20 existing data
resources. The close interaction between PHIDIAS/BBP
and VIOLIN makes bioinformatics analysis of Brucella
vaccines and vaccine targets more efficient.
VIOLIN currently includes vaccine data for 73 patho-
gens. The VIOLIN methods described for Brucella vac-
cine analysis in this report are generic and also feasible
for vaccine studies for other pathogens. It is noted that
Brucella is one of the most annotated pathogens among
these 73 pathogens listed in VIOLIN. The vaccine infor-
mation for many pathogens is not systematically anno-
tated to the extent of Brucella vaccines. More work and
collaborations with the research experts in these patho-
gens are necessary to curate and analyze vaccines and
vaccine candidates for these pathogens.
Conclusions
VIOLIN provides manually curated Brucella vaccine
data and ontology representation of these vaccines using
the Vaccine Ontology (VO). Many tools are developed
in VIOLIN to support literature mining and data cura-
tion. Examples of data stored in the VIOLIN database
include protective Brucella antigens and host responses
induced by different Brucella vaccines. Brucella vaccine
targets may be predicted using the VIOLIN Vaxign pro-
gram. Various Brucella vaccine data can be queried
using user-friendly web query programs in VIOLIN. The
VIOLIN approach is generic and can be used for ana-
lyses of vaccines against other pathogens and infection
diseases.
Methods
Literature mining of Brucella vaccines using VIO-
LIN: The information of all PubMed papers associated
with Brucella vaccine and vaccination were downloaded
from the PubMed web service. The literature contents
were processed using VIOLIN literature mining pipe-
lines [8]. The processed results are available for users to
analyzed using individual VIOLIN literature mining
programs.
Bioinformatics curation of Brucella vaccines in
VIOLIN: Brucella vaccine curation was performed on
the VIOLIN web page using the Limix literature mining
and curation system [7]. Limix allows data curators to
submit data to the website, data reviewers to review and
approve the submitted data, and eventual publication of
high quality data. Specifically, a VIOLIN curator curates
and compiles relevant information on vaccine
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credible websites. The curated information is initially
saved as a draft document and, when completed, is sub-
mitted to a MySQL database. The data submitted is
initially invisible to the public and subject to critical
review by an expert reviewer. Once approved, data
becomes public and available for users to query. The
database administrator manages users’ accounts and
curation tasks. The VIOLIN database is routinely main-
tained by the database administrator. Published database
content is periodically reviewed to ensure that new, per-
tinent information is captured. When new information
is found, a curator and/or a domain expert will update
the database content using the standard procedure
described above. In addition, the VIOLIN team also per-
iodically emails the authors of new vaccine research
p u b l i c a t i o n sa n de n c o u r a g e st h e mt os u b m i tt h e i rd a t a
through the VIOLIN online submission system. VIOLIN
also includes internally developed scripts to automati-
cally update gene annotations based on updated records
from existing databases (e.g., NCBI Gene database).
VO representation of Brucella vaccines: Manually
curated Brucella vaccines are entered into VO by fol-
lowing the VO development standards [27]. The VO is
edited by Protégé (http://protege.stanford.edu/). The
FACT++ OWL reasoner [10] is used to obtain inferred
Brucella vaccine hierarchy.
Vaxign prediction of Brucella vaccine targets: All
ten Brucella genomes stored in the NCBI RefSeq data-
base were used for prediction of Brucella vaccine tar-
gets. The genome of B. abortus strains 2308 was used as
a seed genome. The other genomes include five
sequenced virulent strains from three main pathogenic
Brucella species: B. abortus strain 9-941), B. melitensis
strains 16M and ATCC 23457, and B. suis strains 1330
and ATCC 23445. These strain are pathogenic to
human. The genome of Brucella vaccine strain S19 was
also included in this study for comparison purposes.
The other three Brucella genomes are from B. ovis
strain ATCC 25840, B. canis ATCC 23365, and B.
microti strain CCM 4915. More Brucella genomes have
been sequenced and available at http://www.broadinsti-
tute.org/annotation/genome/brucella_group. Since the
annotations are not yet finished and their records are
not stored in the NCBI RefSeq database, these genomes
were not typically used in this study. The Vaxign pipe-
line was executed by using the Brucella genomes as
input data. The processed results were stored in the
Vaxign database. The Vaxign web query interface was
used to query and analyzed the predicted results.
Query of Brucella vaccine information in VIOLIN:
All manually curated or computational processed data
can be queried through various VIOLIN web pages.
Selected query functions are described in detail in the
body of this manuscript.
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